Primary bilateral tuberculous otitis media with peripheral facial paralysis: a case report and literature review.

Tuberculous otitis media (TOM) is a rare disease. This study presents our experience in the diagnosis and treatment of TOM. A 49-year-old female had repeated ear discharge, vertigo, and severe hearing loss for six years, and underwent mastoid surgery four times because she was misdiagnosed with chronic suppurative otitis media.

Ginsenoside Rh2 alleviates tumor-associated depression in a mouse model of colorectal carcinoma.

Previous studies reported remarkable high incidence of depression in cancer patients compared with the general population. Colorectal carcinoma (CRC) is one of the most frequent malignancies worldwide and has been found to be one of the malignancies with the highest incidence of patient depression. Thus, strategies that may alleviate CRC-associated depression may significantly improve the patients' life quality and outcome of the therapy.

Diagnostic value of CT artifacts for solitary coarse calcifications in thyroid nodules.

This study aimed to estimate the diagnostic value of CT artifacts for solitary coarse calcifications (SCC) in thyroid nodules. A total of 78 SCCs (coarse calcifications >2 mm, no definite mass lesion around calcification) in 63 cases received surgery from Jan 2009 to Jun 2014 were enrolled, including 52 nodular goiters (NG) in 41 cases and 26 papillary thyroid carcinomas (PTC) in 22 cases. The CT artifacts in NGs and PTCs were recorded, and its sensitivity, specificity, positive predictive value, negative predictive value, false positive rate, false negative rate and accuracy for the diagnosis of NG were calculated.

Mechanism of kidney injury caused by bevacizumab in rats.

Objective: We investigate kidney injury caused by high dose bevacizumab to uncover the possible mechanisms involving in this process.

Methods: Forty rats were divided into four groups: cisplation group (treated with 1 mg/kg cisplation), Bev-high group (treated with 5 mg/kg bevacizumab); Bev-low group (treated with 2.5 mg/kg bevacizumab) and control group (treated with saline).